Company profile · Sponsor
Genmab
Genmab A/S
- Pipeline
- 24
- Drugs
- 0
- Patents
- 0
Quick answer
Genmab (ED2DA83) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..
Company facts
Pipeline (24)
Search pipeline →-
BENDAMUSTINE , TOCILIZUMAB , SILTUXIMAB , GEMCITABINE , ANAKINRA , Epcoritamab, DIPHENHYDRAMINE , PARACETAMOL , DEXAMETHASONE , RITUXIMAB , OXALIPLATIN , Epcoritamab
Genmab
B-cell Lymphoma
1 trial -
DOXORUBICIN , Rinatabart Sesutecan, PACLITAXEL
Genmab
Endometrial Cancer Advanced, Recurrent, Metastatic, or Primary Unresectable Endometrial Cancer
1 trial -
METHYLPREDNISOLONE , CellCept 500 mg film-coated tablets, PREDNISONE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOCETAXEL , ANAKINRA , RoActemra 20 mg/mL concentrate for solution for infusion, DEXAMETHASONE , Acasunlimab
Genmab
Non-Small Cell Lung Cancer
1 trial -
PEGFILGRASTIM , PACLITAXEL , DOXORUBICIN , Rinatabart Sesutecan, GEMCITABINE , TOPOTECAN
Genmab
Platinum-resistant Ovarian Cancer
1 trial -
Abraxane 5 mg/ml powder for dispersion for infusion., PEMETREXED , GEN1042 DP, CARBOPLATIN , FLUOROURACIL , PACLITAXEL , PEMBROLIZUMAB, GEMCITABINE , CISPLATIN
Genmab
Malignant solid tumors: Patients with relapsed or refractory, advanced and/or metastatic melanoma, Non-Small Cell Lung Cancer (NSCLC), Head and neck squamous cell carcinoma (HNSCC), Panctreatic ductal adenocarcinoma (PDAC) or Colorectal Cancer (CRC).
1 trial -
Acasunlimab, Abraxane 5 mg/ml powder for dispersion for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pemetrexed Accord 100 mg powder for concentrate for solution for infusion., Cisplatin 1mg/ml Injection BP, Carboplatin 10 mg/ml Intravenous Infusion, Pazenir 5 mg/ml powder for dispersion for infusion., Abraxane 5 mg/ml powder for dispersion for infusion.
Genmab
Malignant solid tumors: endometrial carcinoma (EC), urothelial carcinoma (UC), triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck (SCCHN), or cervical cancer.
1 trial -
Acasunlimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion
Genmab
Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), Metastatic Cutaneous Melanoma (Stage IV)
1 trial -
DIPHENHYDRAMINE , ANAKINRA , DEXAMETHASONE , Epcoritamab, SILTUXIMAB , PREDNISOLONE , TOCILIZUMAB , PARACETAMOL , Epcoritamab
Genmab
Lymphoma of B-cell origin
1 trial -
Epcoritamab, Epcoritamab, PARACETAMOL , ANAKINRA , LENALIDOMIDE , DEXAMETHASONE , DIPHENHYDRAMINE , SILTUXIMAB , TOCILIZUMAB
Genmab
DIFFUSE LARGE B CELL LYMPHOMA
1 trial -
GEN1042 DP, PEMBROLIZUMAB
Genmab
Metastatic Solid Malignant tumors
1 trial -
GEN1047 DP
Genmab
Malignant Solid Tumors
1 trial -
GEN1078 DP
Genmab
Malignant solid tumors
1 trial -
GEN3014 DP, DARZALEX 1800 mg solution for injection
Genmab
Relapsed or Refractory Multiple Myeloma (RRMM) Diffuse Large B Cell Lymphoma (DLBCL) Acute Myeloid Leukemia (AML)
1 trial -
HuMax-TF-ADC, CARBOPLATIN , PEMBROLIZUMAB , BEVACIZUMAB
Genmab
Recurrent or stage IVB cervical cancer
1 trial -
KEYTRUDA 25 mg/mL concentrate for solution for infusion, Acasunlimab
Genmab
Malignant Solid Tumors - Non Small Cell Lung Cancer
1 trial -
PEGFILGRASTIM , Rinatabart Sesutecan
Genmab
Locally advanced or metastatic Non-Small Cell Lung Cancer
1 trial -
PEMETREXED DISODIUM, PEMBROLIZUMAB, PEMBROLIZUMAB, PACLITAXEL, GEN1055 DP, CISPLATIN, GEMCITABINE, PACLITAXEL ALBUMIN-BOUND, CARBOPLATIN
Genmab
Malignant Solid Tumors
1 trial -
SILTUXIMAB , PREDNISOLONE , CYCLOPHOSPHAMIDE , CARBOPLATIN , PARACETAMOL , ETOPOSIDE , VINCRISTINE , LENALIDOMIDE , DIPHENHYDRAMINE , GEMCITABINE , PREDNISONE , OXALIPLATIN , TOCILIZUMAB , Epcoritamab, Epcoritamab, DEXAMETHASONE , DOXORUBICIN , CYTARABINE , RITUXIMAB , IFOSFAMIDE , ANAKINRA , BENDAMUSTINE
Genmab
Lymphoma of B-cell origin
1 trial -
VENETOCLAX , Epcoritamab, Epcoritamab, VINCRISTINE , Jaypirca 100 mg film-coated tablets, DOXORUBICIN , Jaypirca 50 mg film-coated tablets, CYCLOPHOSPHAMIDE , PREDNISOLONE , LENALIDOMIDE , RITUXIMAB
Genmab
Chronic Lymphocytic Leukemia
1 trial -
A Study of GEN1106 in Participants with Solid Tumors
Genmab
Metastatic or advanced malignant solid tumors
1 trial -
First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)
Genmab
Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
1 trial -
Study of safety and antitumor activity of GEN1056 in participants with advanced solid tumors
Genmab
Advanced solid tumors
1 trial -
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants with Advanced Solid Tumors
Genmab
Advanced Malignant Solid Tumors
1 trial -
Trial to assess the safety and antitumor activity of GEN1057 on malignant solid tumors
Genmab
Metastatic or advanced malignant solid tumors
1 trial
Frequently asked questions
What is Genmab?
Genmab (ED2DA83) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..
What pipeline programs does Genmab sponsor?
We track 24 ClinicalTrials.gov-linked programs for Genmab, including BENDAMUSTINE , TOCILIZUMAB , SILTUXIMAB , GEMCITABINE , ANAKINRA , Epcoritamab, DIPHENHYDRAMINE , PARACETAMOL , DEXAMETHASONE , RITUXIMAB , OXALIPLATIN , Epcoritamab and 23 more. Open each program for phase, modality, NCT IDs, and indication details.
Where does Genmab company data come from?
Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.